UBS Group’s Dermata Therapeutics Warrant DRMAW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20 | Buy |
+1,304
| New | +$25 | ﹤0.01% | 10293 |
|
|
2025
Q4 | – | Sell |
-1,279
| Closed | -$22 | – | 10633 |
|
|
2025
Q3 | $22 | Sell |
1,279
-601
| -32% | -$12 | ﹤0.01% | 10124 |
|
|
2025
Q2 | $34 | Sell |
1,880
-737
| -28% | -$14 | ﹤0.01% | 10082 |
|
|
2025
Q1 | $44 | Sell |
2,617
-1,525
| -37% | -$36 | ﹤0.01% | 10025 |
|
|
2024
Q4 | $46 | Sell |
4,142
-100
| -2% | -$1 | ﹤0.01% | 9713 |
|
|
2024
Q3 | $42 | Sell |
4,242
-800
| -16% | -$11 | ﹤0.01% | 9251 |
|
|
2024
Q2 | $71 | Buy |
5,042
+3,557
| +240% | +$40 | ﹤0.01% | 9204 |
|
|
2024
Q1 | $15 | Sell |
1,485
-1,868
| -56% | -$29 | ﹤0.01% | 9059 |
|
|
2023
Q4 | $23 | Sell |
3,353
-2,257
| -40% | -$35 | ﹤0.01% | 9063 |
|
|
2023
Q3 | $101 | Buy |
+5,610
| New | +$136 | ﹤0.01% | 8882 |
|
|
2023
Q2 | – | Sell |
-1,800
| Closed | -$36 | – | 9055 |
|
|
2023
Q1 | $36 | Sell |
1,800
-5,105
| -74% | -$181 | ﹤0.01% | 9370 |
|
|
2022
Q4 | $138 | Sell |
6,905
-2,195
| -24% | -$70 | ﹤0.01% | 10360 |
|
|
2022
Q3 | $1K | Buy |
+9,100
| New | +$899 | ﹤0.01% | 9944 |
|
|
2022
Q2 | – | Sell |
-3,267
| Closed | -$1K | – | 10428 |
|
|
2022
Q1 | $1K | Sell |
3,267
-3,693
| -53% | -$1.04K | ﹤0.01% | 9858 |
|
|
2021
Q4 | $3K | Buy |
6,960
+3,960
| +132% | +$3.12K | ﹤0.01% | 9652 |
|
|
2021
Q3 | $2K | Buy |
+3,000
| New | +$3.08K | ﹤0.01% | 8941 |
|
Other funds holding DRMAW
UBS Group's DRMAW Position: Q1 2026 in Review
UBS Group opened a new position in Dermata Therapeutics Warrant (DRMAW) in Q1 2026: 1,304 shares worth $20. The stake represents ﹤0.01% of the portfolio and ranks #10293 among its holdings. This is a return to the name: UBS Group previously reported a position in DRMAW as recently as Q3 2025.
UBS Group first reported a position in DRMAW in Q3 2021 and has held it in 16 quarters since. The position peaked at $3K in Q4 2021. 2 funds tracked by Wall St. Rank hold DRMAW as of Q1 2026.
- UBS Group held 1,304 shares of Dermata Therapeutics Warrant worth $20 as of Q1 2026.
- Dermata Therapeutics Warrant was a new UBS Group position in Q1 2026.
- Dermata Therapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10293 holding.
- UBS Group first reported a position in Dermata Therapeutics Warrant in Q3 2021 and has held it in 16 quarters since.
- UBS Group's Dermata Therapeutics Warrant position peaked at $3K in Q4 2021.
- 2 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.